Evoke Pharma Inc Total Liabilities

Latest as of September 2025: $12.29 Million USD

Evoke Pharma Inc total liabilities. Based on the latest financial reports, Evoke Pharma Inc (EVOK) has total liabilities worth $12.29 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Evoke Pharma Inc to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Evoke Pharma Inc (2011–2024)

Total liabilities of Evoke Pharma Inc from 2011 to 2024. This chart illustrates how Evoke Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.

Evoke Pharma Inc Competitors by Total Liabilities

The table below lists competitors of Evoke Pharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
STS Group AG XETRA:SF3	Germany	€183.60 Million
Hubei Geoway Investment Co Ltd SHG:600462	China	CN¥310.62 Million
Jericho Oil Corp V:JEV	Canada	CA$5.98 Million
Youlife Group Inc. American Depositary Shares NASDAQ:YOUL	USA	$489.61 Million
RENN Fund Inc NYSE MKT:RCG	USA	$95.59K
Seko S.A. WAR:SEK	Poland	zł51.52 Million
Spacenet Enterprises India Limited NSE:SPCENET	India	Rs496.11 Million
PJX Resources Inc V:PJX	Canada	CA$275.29K

Liability Composition Analysis (2011–2024)

This chart breaks down Evoke Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Evoke Pharma Inc.

Liquidity & Leverage Metrics

Evoke Pharma Inc Total Liabilities Ratios Explained

Evoke Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.27	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.65	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Evoke Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Evoke Pharma Inc (2011–2024)

The table below shows the annual total liabilities of Evoke Pharma Inc from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	$10.48 Million	+8.63%
2023-12-31	$9.65 Million	+24.22%
2022-12-31	$7.77 Million	+10.67%
2021-12-31	$7.02 Million	-44.52%
2020-12-31	$12.65 Million	+527.70%
2019-12-31	$2.02 Million	+23.29%
2018-12-31	$1.63 Million	-71.70%
2017-12-31	$5.78 Million	+4.89%
2016-12-31	$5.51 Million	-9.24%
2015-12-31	$6.07 Million	-0.75%
2014-12-31	$6.11 Million	+60.73%
2013-12-31	$3.80 Million	-80.77%
2012-12-31	$19.78 Million	+6.55%
2011-12-31	$18.56 Million	--

About Evoke Pharma Inc

NASDAQ:EVOK USA Drug Manufacturers - Specialty & Generic

Market Cap

$48.40 Million

Market Cap Rank

#25120 Global

#5339 in USA

Share Price

$28.10

Change (1 day)

-6.02%

52-Week Range

$10.63 - $31.00

All Time High

$1568.16